TScan Therapeutics (TCRX) Change in Accured Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has reported Change in Accured Expenses for 7 consecutive years, with $904000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 116.7% year-over-year to $904000.0; the TTM figure through Mar 2026 stood at -$908000.0 (down 226.11% YoY), while the FY2025 annual figure was -$7.2 million, down 259.44% from the prior year.
• Change in Accured Expenses advanced to $904000.0 in Q1 2026 per TCRX's latest filing, from -$3.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.7 million in Q4 2024 and bottomed at -$5.4 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $164411.8 across 5 years, with a median of $783000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 179.33% in 2024 and fell as far as 317.37% in 2024.
• TScan Therapeutics' Change in Accured Expenses stood at $1.3 million in 2022, then declined by 0.91% to $1.3 million in 2023, then surged by 179.33% to $3.7 million in 2024, then plunged by 192.16% to -$3.4 million in 2025, then soared by 126.79% to $904000.0 in 2026.
• Business Quant data shows TCRX's Change in Accured Expenses at $904000.0 in Q1 2026, -$3.4 million in Q4 2025, and -$1.1 million in Q3 2025.